Table 2.
Overall study population and available number of samples for assessment of each study outcome
|
Cancer cohort (n=151) |
Healthy controls (n=54) | |||
|---|---|---|---|---|
| Solid cancers (n=95) | Haematological cancers (n=56) | |||
| Overall study population | ||||
| Received first dose | 95/95 (100%) | 56/56 (100%) | 54/54 (100%) | |
| Received day 21 boost | 25/95 (26%) | 6/56 (11%) | 16/54 (30%) | |
| Awaiting delayed second dose boost | 69/95* (73%) | 49/56*(88%) | 38/54 (70%) | |
| Study outcome | ||||
| Anti-SARS-CoV-2 IgG response | ||||
| Pre-vaccination baseline samples | 55/95 (58%) | 34/56 (61%) | 12/54 (22%) | |
| First-dose efficacy at week 3 | 56/95 (59%) | 44/56 (79%) | 34/54 (63%) | |
| Efficacy at week 5: no boost | 33/95 (35%) | 36/56 (64%) | 21/54 (39%) | |
| Efficacy at week 5 after day 21 boost | 19/95 (20%) | 5/56 (9%) | 12/54 (22%) | |
| Neutralisation assays | ||||
| First-dose efficacy at week 3 | 54/95 (57%) | 39/56 (70%) | 32/54 (59%) | |
| Efficacy at week 5: no boost | 21/95 (22%) | 25/56 (45%) | 18/54 (33%) | |
| Efficacy at week 5 after day 21 boost | 25/95 (26%) | 5/56 (9%) | 12/54 (22%) | |
| T-cell vaccine response | ||||
| Pre-vaccination baseline samples | 4/95 (4%) | 3/56 (5%) | 2/54 (4%) | |
| First-dose efficacy at week 3 | 31/95 (33%) | 18/56 (32%) | 17/54 (31%) | |
| Efficacy at week 5: no boost | 15/95 (16%) | 18/56 (32%) | 13/54 (24%) | |
| Efficacy at week 5 after day 21 boost | 16/95 (17%) | 4/56 (7%) | 3/54 (6%) | |
| Seropositive or SARS-CoV-2 swab positive | ||||
| Excluded from overall immune efficacy analysis | 9/95 (9%) | 3/56 (5%) | 5/54 (9%) | |
| Adverse events | ||||
| Following first dose | 90/95 (95%) | 50/56 (89%) | 40/54 (74%) | |
| Following week 3 booster | 25/25 (100%) | 6/6 (100%) | 16/16 (100%) | |
Data are n/N (%).
*
Two COVID-19-related deaths before receiving the second dose of the vaccine.